Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer

Kotoe Takayoshi, Hitoshi Kusaba, Masato Uenomachi, Kenji Mitsugi, Chinatsu Makiyama, Akitaka Makiyama, Keita Uchino, Tsuyoshi Shirakawa, Yoshihiro Shibata, Yudai Shinohara, Kyoko Inadomi, Kenji Tsuchihashi, Shuji Arita, hiroshi ariyama, Taito Esaki, Koichi Akashi, Eishi Baba

研究成果: ジャーナルへの寄稿記事

5 引用 (Scopus)

抄録

Purpose: Standard therapy for advanced small bowel adenocarcinoma (SBA) has not yet been established. The present study assessed the efficacy and safety of chemotherapy (CT) in association with molecular targeting approaches for SBA. Methods: The histories of 33 advanced SBA patients from six different institutions in Japan, who received CT from 2008 to 2016, were retrospectively examined for background, clinical course and outcome. Results: Median patient age was 65 years (range 39–83). Primary tumor was located in the duodenum in 21 patients (67%), the ampulla of Vater in three patients (9%), the jejunum in seven patients (21%) and the ileum in one patient (3%). Histologically, well-to-moderately and poorly differentiated adenocarcinoma were identified in 20 (61%) and nine (27%) patients, respectively. Thirteen patients received a single CT regimen, seven patients received two types of CT regimen, and 13 patients received three or more CT regimens. As first-line CT, modified FOLFOX6, capecitabine plus oxaliplatin, and S-1 plus cisplatin were employed in 13, 1, and 4 patients, respectively. The response rate (RR) and median progression-free survival (PFS) were 25% and 6.0 months, respectively. Median overall survival (OS) was 13.0 months. Nine out of the 33 patients received bevacizumab-containing CT and three received cetuximab-containing CT. Median OS of bevacizumab-containing CT patients was 21.9 months. No unexpected serious adverse events were observed. Conclusions: The analysis indicates that combination CT for advanced SBA is associated with modest efficacy and safety, and bevacizumab-containing CT may contribute to favorable outcome in these patients.

元の言語英語
ページ(範囲)333-342
ページ数10
ジャーナルCancer Chemotherapy and Pharmacology
80
発行部数2
DOI
出版物ステータス出版済み - 8 1 2017

Fingerprint

Intestinal Neoplasms
Chemotherapy
Drug Therapy
Adenocarcinoma
oxaliplatin
Bevacizumab
Ampulla of Vater
Safety
Survival
Cisplatin
Tumors
Jejunum
Combination Drug Therapy
Ileum
Duodenum

All Science Journal Classification (ASJC) codes

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

これを引用

Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer. / Takayoshi, Kotoe; Kusaba, Hitoshi; Uenomachi, Masato; Mitsugi, Kenji; Makiyama, Chinatsu; Makiyama, Akitaka; Uchino, Keita; Shirakawa, Tsuyoshi; Shibata, Yoshihiro; Shinohara, Yudai; Inadomi, Kyoko; Tsuchihashi, Kenji; Arita, Shuji; ariyama, hiroshi; Esaki, Taito; Akashi, Koichi; Baba, Eishi.

:: Cancer Chemotherapy and Pharmacology, 巻 80, 番号 2, 01.08.2017, p. 333-342.

研究成果: ジャーナルへの寄稿記事

Takayoshi, K, Kusaba, H, Uenomachi, M, Mitsugi, K, Makiyama, C, Makiyama, A, Uchino, K, Shirakawa, T, Shibata, Y, Shinohara, Y, Inadomi, K, Tsuchihashi, K, Arita, S, ariyama, H, Esaki, T, Akashi, K & Baba, E 2017, 'Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer', Cancer Chemotherapy and Pharmacology, 巻. 80, 番号 2, pp. 333-342. https://doi.org/10.1007/s00280-017-3371-0
Takayoshi, Kotoe ; Kusaba, Hitoshi ; Uenomachi, Masato ; Mitsugi, Kenji ; Makiyama, Chinatsu ; Makiyama, Akitaka ; Uchino, Keita ; Shirakawa, Tsuyoshi ; Shibata, Yoshihiro ; Shinohara, Yudai ; Inadomi, Kyoko ; Tsuchihashi, Kenji ; Arita, Shuji ; ariyama, hiroshi ; Esaki, Taito ; Akashi, Koichi ; Baba, Eishi. / Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer. :: Cancer Chemotherapy and Pharmacology. 2017 ; 巻 80, 番号 2. pp. 333-342.
@article{f12b79e761584d52beb076aa37eb52f5,
title = "Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer",
abstract = "Purpose: Standard therapy for advanced small bowel adenocarcinoma (SBA) has not yet been established. The present study assessed the efficacy and safety of chemotherapy (CT) in association with molecular targeting approaches for SBA. Methods: The histories of 33 advanced SBA patients from six different institutions in Japan, who received CT from 2008 to 2016, were retrospectively examined for background, clinical course and outcome. Results: Median patient age was 65 years (range 39–83). Primary tumor was located in the duodenum in 21 patients (67{\%}), the ampulla of Vater in three patients (9{\%}), the jejunum in seven patients (21{\%}) and the ileum in one patient (3{\%}). Histologically, well-to-moderately and poorly differentiated adenocarcinoma were identified in 20 (61{\%}) and nine (27{\%}) patients, respectively. Thirteen patients received a single CT regimen, seven patients received two types of CT regimen, and 13 patients received three or more CT regimens. As first-line CT, modified FOLFOX6, capecitabine plus oxaliplatin, and S-1 plus cisplatin were employed in 13, 1, and 4 patients, respectively. The response rate (RR) and median progression-free survival (PFS) were 25{\%} and 6.0 months, respectively. Median overall survival (OS) was 13.0 months. Nine out of the 33 patients received bevacizumab-containing CT and three received cetuximab-containing CT. Median OS of bevacizumab-containing CT patients was 21.9 months. No unexpected serious adverse events were observed. Conclusions: The analysis indicates that combination CT for advanced SBA is associated with modest efficacy and safety, and bevacizumab-containing CT may contribute to favorable outcome in these patients.",
author = "Kotoe Takayoshi and Hitoshi Kusaba and Masato Uenomachi and Kenji Mitsugi and Chinatsu Makiyama and Akitaka Makiyama and Keita Uchino and Tsuyoshi Shirakawa and Yoshihiro Shibata and Yudai Shinohara and Kyoko Inadomi and Kenji Tsuchihashi and Shuji Arita and hiroshi ariyama and Taito Esaki and Koichi Akashi and Eishi Baba",
year = "2017",
month = "8",
day = "1",
doi = "10.1007/s00280-017-3371-0",
language = "English",
volume = "80",
pages = "333--342",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "2",

}

TY - JOUR

T1 - Suggestion of added value by bevacizumab to chemotherapy in patients with unresectable or recurrent small bowel cancer

AU - Takayoshi, Kotoe

AU - Kusaba, Hitoshi

AU - Uenomachi, Masato

AU - Mitsugi, Kenji

AU - Makiyama, Chinatsu

AU - Makiyama, Akitaka

AU - Uchino, Keita

AU - Shirakawa, Tsuyoshi

AU - Shibata, Yoshihiro

AU - Shinohara, Yudai

AU - Inadomi, Kyoko

AU - Tsuchihashi, Kenji

AU - Arita, Shuji

AU - ariyama, hiroshi

AU - Esaki, Taito

AU - Akashi, Koichi

AU - Baba, Eishi

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Purpose: Standard therapy for advanced small bowel adenocarcinoma (SBA) has not yet been established. The present study assessed the efficacy and safety of chemotherapy (CT) in association with molecular targeting approaches for SBA. Methods: The histories of 33 advanced SBA patients from six different institutions in Japan, who received CT from 2008 to 2016, were retrospectively examined for background, clinical course and outcome. Results: Median patient age was 65 years (range 39–83). Primary tumor was located in the duodenum in 21 patients (67%), the ampulla of Vater in three patients (9%), the jejunum in seven patients (21%) and the ileum in one patient (3%). Histologically, well-to-moderately and poorly differentiated adenocarcinoma were identified in 20 (61%) and nine (27%) patients, respectively. Thirteen patients received a single CT regimen, seven patients received two types of CT regimen, and 13 patients received three or more CT regimens. As first-line CT, modified FOLFOX6, capecitabine plus oxaliplatin, and S-1 plus cisplatin were employed in 13, 1, and 4 patients, respectively. The response rate (RR) and median progression-free survival (PFS) were 25% and 6.0 months, respectively. Median overall survival (OS) was 13.0 months. Nine out of the 33 patients received bevacizumab-containing CT and three received cetuximab-containing CT. Median OS of bevacizumab-containing CT patients was 21.9 months. No unexpected serious adverse events were observed. Conclusions: The analysis indicates that combination CT for advanced SBA is associated with modest efficacy and safety, and bevacizumab-containing CT may contribute to favorable outcome in these patients.

AB - Purpose: Standard therapy for advanced small bowel adenocarcinoma (SBA) has not yet been established. The present study assessed the efficacy and safety of chemotherapy (CT) in association with molecular targeting approaches for SBA. Methods: The histories of 33 advanced SBA patients from six different institutions in Japan, who received CT from 2008 to 2016, were retrospectively examined for background, clinical course and outcome. Results: Median patient age was 65 years (range 39–83). Primary tumor was located in the duodenum in 21 patients (67%), the ampulla of Vater in three patients (9%), the jejunum in seven patients (21%) and the ileum in one patient (3%). Histologically, well-to-moderately and poorly differentiated adenocarcinoma were identified in 20 (61%) and nine (27%) patients, respectively. Thirteen patients received a single CT regimen, seven patients received two types of CT regimen, and 13 patients received three or more CT regimens. As first-line CT, modified FOLFOX6, capecitabine plus oxaliplatin, and S-1 plus cisplatin were employed in 13, 1, and 4 patients, respectively. The response rate (RR) and median progression-free survival (PFS) were 25% and 6.0 months, respectively. Median overall survival (OS) was 13.0 months. Nine out of the 33 patients received bevacizumab-containing CT and three received cetuximab-containing CT. Median OS of bevacizumab-containing CT patients was 21.9 months. No unexpected serious adverse events were observed. Conclusions: The analysis indicates that combination CT for advanced SBA is associated with modest efficacy and safety, and bevacizumab-containing CT may contribute to favorable outcome in these patients.

UR - http://www.scopus.com/inward/record.url?scp=85021297395&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021297395&partnerID=8YFLogxK

U2 - 10.1007/s00280-017-3371-0

DO - 10.1007/s00280-017-3371-0

M3 - Article

VL - 80

SP - 333

EP - 342

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 2

ER -